https://glp1briefing.comWhat happens next in GLP-1 — and when.en-usFri, 04 Sep 2026 06:06:17 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866None-2026-09-03-new. — (ELI LILLY AND CO). Detected 2026-09-03.Thu, 03 Sep 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806None-2026-09-03-new. — (ELI LILLY AND CO). Detected 2026-09-03.Thu, 03 Sep 2026 00:00:00 +0000https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776bNone-2026-09-03-field_changed. — (). Detected 2026-09-03.Thu, 03 Sep 2026 00:00:00 +0000https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0None-2026-09-03-field_changed. — (). Detected 2026-09-03.Thu, 03 Sep 2026 00:00:00 +0000https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0None-2026-09-03-field_changed. — (). Detected 2026-09-03.Thu, 03 Sep 2026 00:00:00 +0000https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0None-2026-09-03-field_changed. — (). Detected 2026-09-03.Thu, 03 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06803888NCT06803888-2026-09-03-enrollment125 → 140 participants. P4 — Bariatric Surgery vs. Semaglutide vs. Tirzepatide (Ali Aminian). Detected 2026-09-03.Thu, 03 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07801820NCT07801820-2026-09-03-newRECRUITING. P2 — Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus (Shanghai Minwei Biotechnology Co., Ltd). Detected 2026-09-03.Thu, 03 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06762314NCT06762314-2026-09-02-completion_moved2027-09-20 → 2026-01-20 (20 months earlier). P2 — Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (Mostafa Bahaa). Detected 2026-09-02.Wed, 02 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06762314NCT06762314-2026-09-02-statusRECRUITING → COMPLETED. P2 — Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (Mostafa Bahaa). Detected 2026-09-02.Wed, 02 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06762314NCT06762314-2026-09-02-enrollment105 → 114 participants. P2 — Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (Mostafa Bahaa). Detected 2026-09-02.Wed, 02 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06557811NCT06557811-2026-09-02-statusNOT_YET_RECRUITING → UNKNOWN. P4 — Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction (University of Sao Paulo General Hospital). Detected 2026-09-02.Wed, 02 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07797036NCT07797036-2026-09-01-newNOT_YET_RECRUITING. P2/P3 — Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes (University of Massachusetts, Worcester). Detected 2026-09-01.Tue, 01 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06299098NCT06299098-2026-09-01-completion_moved2026-05-06 → 2026-06-16 (1 months later). P2 — A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation (Regeneron Pharmaceuticals). Detected 2026-09-01.Tue, 01 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07796477NCT07796477-2026-09-01-newNOT_YET_RECRUITING. P2 — A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin (CSPC Ouyi Pharmaceutical Co., Ltd.). Detected 2026-09-01.Tue, 01 Sep 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07794579NCT07794579-2026-08-31-newNOT_YET_RECRUITING. P3 — A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity (Eli Lilly and Company). Detected 2026-08-31.Mon, 31 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07795164NCT07795164-2026-08-31-newRECRUITING. P3 — Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (Altimmune, Inc.). Detected 2026-08-31.Mon, 31 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06934655NCT06934655-2026-08-31-statusNOT_YET_RECRUITING → RECRUITING. P3 — Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth: A Randomized Clinical Trial (Children's Hospital Los Angeles). Detected 2026-08-31.Mon, 31 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06559722NCT06559722-2026-08-31-statusNOT_YET_RECRUITING → UNKNOWN. P3 — A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes (Tonghua Dongbao Pharmaceutical Co.,Ltd). Detected 2026-08-31.Mon, 31 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06164873NCT06164873-2026-08-31-statusACTIVE_NOT_RECRUITING → UNKNOWN. P3 — A Study of IBI362 9 mg in Chinese Adults With Obesity (Innovent Biologics (Suzhou) Co. Ltd.). Detected 2026-08-31.Mon, 31 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07734311NCT07734311-2026-08-31-statusNOT_YET_RECRUITING → RECRUITING. P3 — A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA) (Hangzhou Sciwind Biosciences Co., Ltd.). Detected 2026-08-31.Mon, 31 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-28-field_changedCurrent. — (). Detected 2026-08-28.Fri, 28 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-28-statusCurrent → To Be Discontinued. — (). Detected 2026-08-28.Fri, 28 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-28-field_changedTo Be Discontinued. — (). Detected 2026-08-28.Fri, 28 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-28-statusTo Be Discontinued → Current. — (). Detected 2026-08-28.Fri, 28 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-28-field_changedCurrent. — (). Detected 2026-08-28.Fri, 28 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT06548490NCT06548490-2026-08-28-completion_moved2027-04 → 2027-04-30. P2 — GLP-1R Agonist Treatment for Opioid Use Disorder (Milton S. Hershey Medical Center). Detected 2026-08-28.Fri, 28 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07191873NCT07191873-2026-08-28-statusNOT_YET_RECRUITING → RECRUITING. P4 — Tirzepatide in Idiopathic Intracranial Hypertension Trial (Duke University). Detected 2026-08-28.Fri, 28 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07657676NCT07657676-2026-08-28-completion_moved2027-10-31 → 2027-12-31 (2 months later). P4 — Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity (China National Center for Cardiovascular Diseases). Detected 2026-08-28.Fri, 28 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866None-2026-08-27-new. — (ELI LILLY AND CO). Detected 2026-08-27.Thu, 27 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866None-2026-08-27-new. — (ELI LILLY AND CO). Detected 2026-08-27.Thu, 27 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637None-2026-08-27-new. — (NOVO). Detected 2026-08-27.Thu, 27 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07154719NCT07154719-2026-08-27-statusACTIVE_NOT_RECRUITING → RECRUITING. P4 — GLP-1R Actions on Muscle and the Skeleton (Pennington Biomedical Research Center). Detected 2026-08-27.Thu, 27 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07790861NCT07790861-2026-08-27-newNOT_YET_RECRUITING. P3 — A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems (Eli Lilly and Company). Detected 2026-08-27.Thu, 27 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806None-2026-08-26-new. — (ELI LILLY AND CO). Detected 2026-08-26.Wed, 26 Aug 2026 00:00:00 +0000https://clinicaltrials.gov/study/NCT07349641NCT07349641-2026-08-26-completion_moved2028-12-31 → 2029-10-31 (10 months later). P2 — A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (National Cancer Institute (NCI)). Detected 2026-08-26.Wed, 26 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-25-statusCurrent → To Be Discontinued. — (). Detected 2026-08-25.Tue, 25 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-25-field_changedTo Be Discontinued. — (). Detected 2026-08-25.Tue, 25 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-25-field_changedCurrent. — (). Detected 2026-08-25.Tue, 25 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/drugshortages/None-2026-08-25-field_changedCurrent. — (). Detected 2026-08-25.Tue, 25 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637NDA209637-44-2026-08-27NOVO — application NDA209637, OZEMPIC. Approved 2026-08-27.Thu, 27 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866NDA215866-44-2026-08-27ELI LILLY AND CO — application NDA215866, MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN. Approved 2026-08-27.Thu, 27 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866NDA215866-45-2026-08-27ELI LILLY AND CO — application NDA215866, MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN. Approved 2026-08-27.Thu, 27 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806NDA217806-41-2026-08-26ELI LILLY AND CO — application NDA217806, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPEN. Approved 2026-08-26.Wed, 26 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934NDA220934-3-2026-08-04ELI LILLY AND CO — application NDA220934, FOUNDAYO. Approved 2026-08-04.Tue, 04 Aug 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=A212972ANDA212972-1-2026-07-01SANDOZ — application ANDA212972, LIRAGLUTIDE. Approved 2026-07-01.Wed, 01 Jul 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256NDA215256-25-2026-06-18NOVO — application NDA215256, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD. Approved 2026-06-18.Thu, 18 Jun 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316NDA218316-7-2026-06-18NOVO — application NDA218316, WEGOVY. Approved 2026-06-18.Thu, 18 Jun 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=A213155ANDA213155-1-2026-06-15MYLAN INSTITUTIONAL — application ANDA213155, LIRAGLUTIDE. Approved 2026-06-15.Mon, 15 Jun 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321NDA206321-24-2026-06-02NOVO — application NDA206321, SAXENDA. Approved 2026-06-02.Tue, 02 Jun 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637NDA209637-38-2026-06-01NOVO — application NDA209637, OZEMPIC. Approved 2026-06-01.Mon, 01 Jun 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256NDA215256-31-2026-05-05NOVO — application NDA215256, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD. Approved 2026-05-05.Tue, 05 May 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316NDA218316-3-2026-05-05NOVO — application NDA218316, WEGOVY. Approved 2026-05-05.Tue, 05 May 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934NDA220934-1-2026-04-01ELI LILLY AND CO — application NDA220934, FOUNDAYO. Approved 2026-04-01.Wed, 01 Apr 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=A212552ANDA212552-1-2026-03-30FRESENIUS KABI USA — application ANDA212552, LIRAGLUTIDE. Approved 2026-03-30.Mon, 30 Mar 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256NDA215256-29-2026-03-19NOVO — application NDA215256, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD. Approved 2026-03-19.Thu, 19 Mar 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316NDA218316-5-2026-03-19NOVO — application NDA218316, WEGOVY. Approved 2026-03-19.Thu, 19 Mar 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469BLA125469-65-2026-03-12ELI LILLY AND CO — application BLA125469, TRULICITY. Approved 2026-03-12.Thu, 12 Mar 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208673BLA208673-23-2026-03-12SANOFI-AVENTIS US — application BLA208673, SOLIQUA 100/33. Approved 2026-03-12.Thu, 12 Mar 2026 00:00:00 +0000https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208471BLA208471-12-2026-03-12SANOFI-AVENTIS US — application BLA208471, ADLYXIN. Approved 2026-03-12.Thu, 12 Mar 2026 00:00:00 +0000